RE:RE:RE:RE:RE:Quick SummaryI listened to that part again so it wasn't an assessed based fundraising Paul was referring to he said they have are a commercial organization which is producing revenues which can be the helping towards the funding.
palinc2000 wrote: Nope[
quote=SPCEO1]I am guessing they could use accounts receivable financing to fund the NASH trial's start.
Wino115 wrote: I don't think that's an exact quote but I could be wrong. I interpreted it as him saying something like ...don't forget we have a commercial business with revenues and we can reorient some of that towards the NASH project. Sort of sounded like, cut costs way down to free up some cash flow for a bit to invest in NASH over the next 3 years. I guess you could theoretically say let's cut sales costs $3mil a year, assume Europe ramps to provide $3mil free cash flow, so we'll have $6mil free cash flow annually, plus hopefully some more in oncology and maybe a license or two for overseas markets; thus getting you to $12 mil a year for the next 3 years. Something like that is what I was thinking but I could be off base.
qwerty22 wrote: "They have a commercial business which can be used as a collateral in order to raise funds."
As I said I missed the presentation. What do people make of scarett's statement here? What came to mind is another convertible or other form of lending. Does it mean something else?
scarlet1967 wrote:
Oncology:
As per new dose escalation slide they dosed first patient with 30mg/m2 second patient 2x30mg/m2=60mg/m2 third patient 2x60mg/m2=120mg/m2 forth patient 1.67x120mg/m2=200mg/m2 fifths patient 200mg/m2x1.5=300mg/m2 and last single and sixth patient 300mg/m2x1.4=420mg/m2, it seems they have started dosing group of 3 patients at 420mg/m2 if no DLT planning to increase the dosage by factor of 1.33(420mg/m2x1.33)560mg/m2 on next group of 3 if DLT they dose a group of 6 if less than 1or more with DLT they increase the dosage by factor of 1.33 again in next group of 6 patients until 1 or more patient shows DLT. He confirmed even at twice the level of Docetaxel their intracellular concentration of anti-cancer agent could be multiples of Docetaxel alone theoretically up to 8 time more.
It looks like the amount of Docetaxel released in blood stream in humans is similar to animals based are incoming data which they haven’t published but are monitoring. Paul mentioned they will be starting the combination therapy (TH19 series+ immunotherapy) possibilities in clinic. Their peptide can potentially conjugate to SN-38 a very potent cytotoxic agent and small interfering RNA (molecule which can regulate and effect the expression of genes) in order to silence the protein responsible for cancer cells growth.
NASH:
They are having conversations with few potential partners failing that they want to fund the trial in a responsible manner without effecting the investors negatively.
They have a commercial business which can be used as a collateral in order to raise funds. Also they will be finding the trial in in installments ”chops of payments” so there is no need to raise huge amount of funds initially.
Legacy drugs:
They are optimistic on Tesamorelin as it seems both passed sales and incoming prescription are rising and Trogarzo (long lasting drug) which “seems to be more relevant now” will be launched in multiple European countries once the pricing is confirmed
[/quote]